2. Signaling Pathways
  3. Immunology/Inflammation
  4. Mucin
  5. Mucin Isoform

Mucin

 

Mucin Related Products (34):

Cat. No. Product Name Effect Purity
  • HY-P99634
    Gatipotuzumab
    		99.204%
    Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).
  • HY-160109
    Ac5GalNTGc
    		98.54%
    Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research.
  • HY-B0264
    Guaifenesin
    		99.86%
    Guaifenesin (Guaiacol glyceryl ether), a constituent of guaiac resin from the wood of Guajacum officinale Linné, is an expectorant. Guaifenesin can alleviate cough discomfortby increasing sputum volume and decreasing its viscosity, thereby promoting effective cough.
  • HY-P99237
    Sofituzumab
    		Inhibitor
    Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a Kd of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model.
  • HY-P99732
    Minretumomab
    		Inhibitor
    Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.
  • HY-W746270
    Guaimesal
    Guaimesal is a new antiphlogistic and mucus-regulating agent. Guaimesal improves bronchitis symptoms.
  • HY-P992131
    Sacomitatug
    		Inhibitor
    Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors.
  • HY-160062A
    S2.2 aptamer sodium scrambled negative control
    		Chemical
    S2.2 aptamer sodium scrambled negative control is the sequence scrambled negative control of S2.2 aptamer sodium.
  • HY-P99591
    Sontuzumab
    		Inhibitor 99.66%
    Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.
  • HY-P2508
    MUC1, mucin core
    MUC1, mucin core is the region of the MUC1 mucin core. MUC1 is a type I transmembrane glycoprotein, and is overexpressed and aberrantly glycosylated in carcinoma cells. MUC1, mucin core protein binds to domain 1 of ICAM-1.
  • HY-N1510
    Kaempferol 3-O-gentiobioside
    		Inhibitor 99.88%
    Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma. It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer.
  • HY-168973
    Fexlamose
    		Inhibitor 99.93%
    Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD).
  • HY-P99962
    Surzebiclimab
    Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer.
  • HY-171270
    Clivatuzumab-MMAE
    		98.71%
    Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) (Clivatuzumab antibody (HY-P99968), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is a humanized anti-mucin monoclonal antibody.
  • HY-P99968
    Clivatuzumab
    		Inhibitor ≥99.0%
    Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
  • HY-P99362
    Ensituximab
    		Inhibitor 99.93%
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
  • HY-P990831
    Anti-MUC1/CD227 Antibody (C595 (NCRC48))
    		Inhibitor
    Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3 κ chimeric antibody inhibitor, targeting to human MUC1/CD227. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) specifically recognizes and binds to the MUC1 protein, which is overexpressed and abnormally glycosylated on the surface of tumor cells, thereby precisely killing cancer cells. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) can be used for the researches of cancer, such as ovarian cancer.
  • HY-P0280
    MUC5AC motif peptide
    		98.97%
    MUC5AC motif peptide is a 16-amino acid fragment of mucin 5.
  • HY-160062
    S2.2 aptamer sodium
    		Chemical
    S2.2 aptamer sodium is a nucleic acid-based MUC1-binding aptamer with high affinity and low toxicity. Upon binding to its target, S2.2 aptamer sodium undergoes a conformational switch and restores fluorescence signal, serving as a targeted imaging agent for MUC1-positive cancer cells. S2.2 aptamer sodium enables targeted delivery to breast cancer cells with overexpressed MUC1. When formulated as the S2.2-PEG-MZF molecular probe, S2.2 aptamer sodium possesses the functions of T2 signal inhibition, magnetic field-induced hyperthermia and targeted magnetic resonance molecular imaging. In the S2.2-PEG-MZF/DOX nanoliposome, S2.2 aptamer sodium supports targeted thermochemotherapy, effectively inhibiting cancer cell proliferation and invasion as well as inducing apoptosis, and is widely used in studies related to breast cancer.
  • HY-160109A
    Ac5GalNTGc epimer
    		Inhibitor 98.39%
    Ac5GalNTGc epimer is an analogue of hexosamine and the racemate of Ac5GalNTGc (HY-160109). Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research.